Edgestream Partners, L.P. Incyte Corp Transaction History

Edgestream Partners, L.P.

$2.29 Billion
Q4 2024

A detailed history of Edgestream Partners, L.P. transactions in Incyte Corp stock. As of the latest transaction made, Edgestream Partners, L.P. holds 61,174 shares of INCY stock, worth $4.41 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

61,174

Previous 22,408 173.0%

Holding current value

$4.41 Million

Previous $1.48 Million 185.28%

% of portfolio

0.18%

Previous 0.07%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$65.08 - $83.38 $2.52 Million - $3.23 Million	38,766 Added 173.0%	61,174 $4.23 Million
Q3 2024 Nov 14, 2024	BUY	$57.33 - $68.61 $1.28 Million - $1.54 Million	22,408 New	22,408 $1.48 Million
Q1 2024 May 10, 2024	BUY	$56.55 - $66.59 $2.23 Million - $2.63 Million	39,478 Added 1197.03%	42,776 $2.44 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $2.83 Million - $3.48 Million	-54,252 Reduced 94.27%	3,298 $207,000
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $2.25 Million - $2.57 Million	38,972 Added 209.78%	57,550 $3.32 Million
Q2 2023 Aug 10, 2023	SELL	$60.95 - $75.51 $151,338 - $187,491	-2,483 Reduced 11.79%	18,578 $1.16 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $1.48 Million - $1.81 Million	21,061 New	21,061 $1.52 Million
Q2 2022 Aug 12, 2022	SELL	$66.18 - $83.18 $1.13 Million - $1.43 Million	-17,144 Reduced 26.33%	47,979 $3.65 Million
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $4.3 Million - $5.19 Million	65,123 New	65,123 $5.17 Million
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $382,423 - $467,907	-5,569 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$79.87 - $87.53 $444,796 - $487,454	5,569 New	5,569 $469,000

Others Institutions Holding INCY

# of Institutions

706

Shares Held

189M

Call Options Held

909K

Put Options Held

489K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.

Account

Edgestream Partners, L.P. Incyte Corp Transaction History